RT Journal Article
SR Electronic
T1 Software development for Autologous Skin substitute production
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.16.21255595
DO 10.1101/2021.04.16.21255595
A1 Guillaume Mestrallet
YR 2021
UL http://medrxiv.org/content/early/2021/04/16/2021.04.16.21255595.abstract
AB The gold-standard for the management of patients affected by large-surface third-degree burns is autologous skin graft. When burns affect <40% total body surface area (TBSA), meshed skin samples harvested from non-affected donor sites can be used as grafts. In more severe cases corresponding to burns affecting >40% TBSA), the donor site surfaces are insufficient. The alternative grafting strategy uses bioengineered skin substitutes that are generated using the own keratinocytes of the patient after ex vivo expansion. Optimal setup of the bioengineering process involved determination of the required graft surface, adjustment of cell quantities, and control of the timing necessary for production. Accordingly, tools to assist the design of personalized protocols will certainly contribute to care quality and cost limitation. Here, I describe the principle of a software-assisted calculation of the required graft surface and keratinocyte numbers needed, according to specific patient clinical characteristics. The software also offers assistance to estimate the Baux score, a method that has been proposed to link the severity of burn injuries and the prognosis for the patient. In conclusion, this software provides a principle of assisted burned patient diagnose and skin substitute bioengineering process which development may facilitate the design of personalized protocols for skin regenerative cell therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There is no need to have an appoval as all data presented here correspond to a fictious patient.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the paper.AAgeAPIApplication Programming InterfaceATamplification timeBCYbiopsy cell yield (number of cells extracted from a biopsy cm2)BSABody Surface AreaBZBiopsy SizeGRC7Growth Rate of Cells in 7 days (average number of cells obtained from a single cell)GZGraft SizeHHeightHTTPHypertext Transfer ProtocolFNCFinal number of cells to seed per cm2 7 days before graftingSTSGSplit Thickness Skin GraftTBSATotal Body Surface AreaTNCRTotal Number of Cells RequiredWHOWorld Health OrganizationWWeight%TBSAPercentage of Total Body Surface Area burned